ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0378

Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics

Atul Deodhar1, Sonam Kiwalkar2, Kim Phung Nguyen3, Rose Quinn3, David Perham4, William Malatestinic5, Rebecca Bolce6, Theresa Hunter5, Pragya Khurana7 and Shireesh Bhalerao4, 1Oregon Health & Science University, Portland, OR, USA, Portland, OR, 2Washington State University, Portland, OR, 3Oregon Health & Science University, Portland, OR, 4Private Practice, Portland, OR, 5Eli Lilly and Company, Indianapolis, IN, 6Eli Lilly and Company, Cincinnati, OH, 7ICON plc, Blue Bell, PA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Epidemiology, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with chronic back pain (CBP; back, buttock, or hip pain ≥ 3 months) where the underlying cause may be axSpA are usually first seen in non-rheumatology settings such as chiropractic clinics. These settings lack consistency in referral to rheumatologists, which may lead to delays in diagnosis. In a previous study1, where chiropractors referred patients with CBP as the primary complaint, originating from sacroiliac (SI) joints according to the chiropractor, plus at least one SpA feature to a rheumatologist, the prevalence of axSpA was found to be 6.8%. The objective of this study was to assess the prevalence of undiagnosed axSpA in patients attending chiropractic clinics with a primary or secondary complaint of CBP, and referred with the Assessment of Spondyloarthritis International Society (ASAS) referral strategy.

Methods: Eligible patients were adults attending one of four chiropractic clinics in the United States between November 2020 and November 2021 with CBP starting before age of 45, without prior diagnosis of SpA. Patients were referred to a rheumatologist for diagnostic assessment via phone consultation if they had ≥1 of the following features: inflammatory back pain (IBP), a family history of SpA, inflammatory bowel disease (IBD), psoriasis, good response to NSAIDs, history of heel pain, uveitis, or peripheral arthritis. The subsequent rheumatology assessment included medical history (telephone interview), laboratory tests (CRP, HLA-B27), x-ray and MRI of SI joints. An academic rheumatologist made the diagnosis of axSpA, peripheral SpA, or absence of SpA.

Results: A total of 3,103 visits were recorded at 4 chiropractic clinics during the study period. Top 10 primary complaints at chiropractic visits are presented in Figure 1. In total, 115 patients were referred, and of the 74 who were eligible and provided consent, 59 (79.7%) reported to have IBP. In total, 65 patients were fully assessed by a rheumatologist, of which 8 (12.3%) had SpA. Five (7.7%) were diagnosed as non-radiographic axSpA (nr-axSpA, fulfilled ASAS classification criteria), 1 (1.5%) radiographic axSpA (fulfilled modified New York criteria), 1 (1.5%) Psoriatic Arthritis without imaging evidence of axial involvement (fulfilled Classification Criteria for Psoriatic Arthritis), and 1 (1.5%) had undifferentiated peripheral SpA (fulfilled ASAS Classification Criteria). Patient characteristics are presented in Table 1. Out of the SpA features, objective parameters such as imaging, presence of psoriasis and positive HLA-B27 had the highest positive likelihood ratio (Table 2).

Conclusion: Twelve percent of patients with CBP referred from chiropractic clinics with the ASAS strategy had undiagnosed SpA, with nr-axSpA being the most common. Our sample indicates that objective features of inflammation have the highest positive likelihood ratio in making the diagnosis of SpA.

1Kiwalkar et al. Chiropractic Axial Spondyloarthritis Study (ORCAS): Interim Results [Abstract] SPARTAN Annual Meeting 2020

Supporting image 1

Figure 1. Top ten primary complaints reported by patients at chiropractic clinics (n=3103)

Supporting image 2

Table 1. Patient demographic and clinical characteristics stratified by rheumatologist’s diagnosis

Supporting image 3

Table 2. Performance of individual SpA features, compared to full diagnostic assessment by rheumatologist


Disclosures: A. Deodhar, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, UCB Pharma, Aurinia, Moonlake; S. Kiwalkar, None; K. Phung Nguyen, None; R. Quinn, None; D. Perham, Eli Lilly; W. Malatestinic, Eli Lilly and Company; R. Bolce, Eli Lilly; T. Hunter, Eli Lilly and Company; P. Khurana, Eli Lilly; S. Bhalerao, Eli Lilly.

To cite this abstract in AMA style:

Deodhar A, Kiwalkar S, Phung Nguyen K, Quinn R, Perham D, Malatestinic W, Bolce R, Hunter T, Khurana P, Bhalerao S. Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-axial-spondyloarthritis-axspa-in-patients-treated-for-chronic-back-pain-in-chiropractic-clinics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-axial-spondyloarthritis-axspa-in-patients-treated-for-chronic-back-pain-in-chiropractic-clinics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology